Laboratory Corporation of America® Holdings Announces 2015 Fourth Quarter and Full Year Results and Provides 2016 Guidance

Record Q4 and 2015 Net Revenue of $2.2 billion and $8.5 billion , respectively Q4 and 2015 Diluted EPS of $1.11 and $4.34 , respectively Record Q4 and 2015 Adjusted EPS of $1.98 and $7.91 , respectively Q4 and 2015 Free Cash Flow of $300 million and $727 million , respectively 2016 Adjusted EPS

LabCorp and Cheeriodicals Spread Cheer to UNC Children’s

CHAPEL HILL & BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 27, 2016-- A team from Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH), along with Cheeriodicals , delivered cheer in the form of 160 big green boxes to patients at N.C. Children’s Hospital during a "Cheeriodicals Day"

LabCorp Announces New Board Member

Richelle Parham Named to the Board of Directors Effective February 8, 2016 BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 7, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that Richelle Parham has been appointed to its Board of Directors, effective February 8,

LabCorp is Scheduled to Present at the 34th Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 6, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the 34 th Annual J.P. Morgan Healthcare Conference . LabCorp’s presentation is scheduled for Wednesday, January 13, 2016 at 11:00 AM (ET) .

Proprietary LabCorp Clinical Decision Support Report Improves Adherence to Chronic Kidney Disease Treatment Guidelines

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the results of a recently published clinical research study that demonstrates improved physician adherence to chronic kidney disease (CKD) treatment guidelines

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Enters into Definitive Agreement to Acquire Assets of Pathology, Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 10, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that it has entered into a definitive agreement to acquire substantially all of the operating assets of Pathology, Inc.

LabCorp Launches New Enhanced Report for Medical Drug Monitoring

The LabCorp MedWatch ® ToxAssure ® report joins a suite of proprietary decision support tools to assist clinicians in patient management BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 30, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that MedTox Laboratories

LabCorp is Scheduled to Present at the 2015 Credit Suisse Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 3, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the 2015 Credit Suisse Healthcare Conference . LabCorp’s presentation is planned for Tuesday, November 10, 2015 at 1:00 PM (ET) .

Laboratory Corporation of America® Holdings Announces 2015 Third Quarter Results

Q3 Net revenue of $2.3 billion , up 46% over last year Q3 Diluted EPS of $1.49 ; Q3 Adjusted EPS of $2.07 , up 15% over last year Q3 Free Cash Flow of $220 million , up 79% over last year 2015 Adjusted EPS guidance updated to $7.80 - $7.95 from $7.75 - $8.00 BURLINGTON, N.C. --(BUSINESS WIRE)--Oct.